Medicare now covers GLP-1s for obesity. Even outside of obesity, Medicare GLP-1 scripts hit ~22 million in 2024 (up 4x from 2019, double 2022).
Now add the biggest indication of all (~20 million clinically eligible Medicare patients over time). Impact still underappreciated.